HuCD34+ NCG Mouse

p.small { line-height: 0.9; } p.big { line-height: 1.8; } The HuCD34+ NCG mouse is produced by engrafting human hematopoietic stem cells (HSCs) into the NCG model. NCG mice are irradiated and intravenously injected with hCD34+ HSCs, which differentiate into a variety of hCD45+ white blood cells (WBCs), including T cells and B cells. The mice are engrafted regularly and available on demand 14 – 16 weeks after engraftment.This model is an ideal in vivo platform with a long survival period and stable reconstitution of immune cells. It can be used in longer-term in vivo studies to test drug efficacy.Characteristics of the model include:Stable engraftment of human WBCsLong-term studiesMulti-lineage engraftmentDisplay robust T cell populationNCG Mouse OriginThe NCG mouse was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to Charles River in 2016. This model was created by sequential CRISPR/Cas9* editing of the Prkdc and Il2rg loci in the NOD/Nju mouse, generating a mouse coisogenic to the NOD/Nju.The NOD/Nju carries a mutation in the Sirpa (SIRP α) gene that allows for the engraftment of foreign hematopoietic stem cells. The Prkdc knockout generates a SCID-like phenotype, lacking proper T cell and B cell formation. The knockout of the Il2rg gene further exacerbates the SCID-like phenotype while additionally resulting in a decrease of NK cell production.*CRISPR/CAS9 is used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.